Everence Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Everence Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-25,990	Closed	-$155K	–	806
2023 Q2	$155K	Hold	25,990	–	–	0.01%	685
2023 Q1	$176	Hold	25,990	–	–	0.01%	705
2022 Q4	$192	Buy	25,990 +15,100	+139%	+$147K	0.02%	701
2022 Q3	$108K	Hold	10,890	–	–	0.01%	709
2022 Q2	$119K	Hold	10,890	–	–	0.01%	704
2022 Q1	$123K	Hold	10,890	–	–	0.01%	724
2021 Q4	$171K	Hold	10,890	–	–	0.01%	742
2021 Q3	$187K	Hold	10,890	–	–	0.02%	705
2021 Q2	$234K	Hold	10,890	–	–	0.02%	649
2021 Q1	$164K	Hold	10,890	–	–	0.01%	703
2020 Q4	$143K	Hold	10,890	–	–	0.01%	683
2020 Q3	$105K	Hold	10,890	–	–	0.01%	663
2020 Q2	$128K	Hold	10,890	–	–	0.02%	626
2020 Q1	$113K	Buy	+10,890	New	+$135K	0.02%	577

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Everence Capital Management's VNDA Position: Q3 2023 in Review

Everence Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q3 2023, closing a stake of 25,990 shares — an estimated $155K sold.

Everence Capital Management first reported a position in VNDA in Q1 2020 and held it in 14 quarters. The position peaked at $234K in Q2 2021. 179 funds tracked by Wall St. Rank hold VNDA as of Q3 2023.

Everence Capital Management reported no remaining Vanda Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Everence Capital Management sold 25,990 Vanda Pharmaceuticals shares in Q3 2023, an estimated $155K.
Everence Capital Management first reported a position in Vanda Pharmaceuticals in Q1 2020 and held it in 14 quarters.
Everence Capital Management's Vanda Pharmaceuticals position peaked at $234K in Q2 2021.
179 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2023.

Based on Everence Capital Management's 13F filing for Q3 2023, filed 16 Oct 2023.